VEGF 188 組換え体(リコンビナント)タンパク質 | Recombinant Mouse VEGF 188

掲載日情報:2015/04/06 現在Webページ番号:160077

R&D Systems社製の高品質なVEGF 188の組換え体タンパク質(Recombinant Mouse VEGF 188)です。
本製品は研究用です。研究用以外には使用できません。

[在庫・価格 :2024年04月27日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
納期 文献数
Recombinant Mouse VEGF 188
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 0
説明文
純度:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.,由来動物:Mouse,M.W.:22.1 kDa (monomer),Genbank:7422,エンドトキシンレベル:<0.01 EU per 1 µg of the protein by the LAL method.,産生:HEK293
別名:MVCD1
Genbank No: 7422
Protein Accession No: Q00731
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 Recombinant Mouse VEGF188 / Anti-Mouse FCRLA Antigen Affinity-purified Polyclonal Antibody
関連記事

[在庫・価格 :2024年04月27日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Recombinant Mouse VEGF 188

文献数: 0

説明文 純度:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.,由来動物:Mouse,M.W.:22.1 kDa (monomer),Genbank:7422,エンドトキシンレベル:<0.01 EU per 1 µg of the protein by the LAL method.,産生:HEK293
別名:MVCD1
Genbank No: 7422
Protein Accession No: Q00731
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 Recombinant Mouse VEGF188 / Anti-Mouse FCRLA Antigen Affinity-purified Polyclonal Antibody
関連記事

バルク注文に関して

バルク包装品も承ります。お気軽にお問合せ下さい。

目次に戻る

CF(Carrier-Free)とは?

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

目次に戻る

Product Details

Source
Human embryonic kidney cell, HEK293-derived, Ala27-Arg214
Accession
Q00731
Structure
Disulfide-linked homodimer
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Predicted Molecular Mass
22.1 kDa (monomer)
SDS-PAGE
28-30 kDa, reducing conditions
Activity
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells.Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87

目次に戻る

Additional Information

Molecule Information
VEGF
Aliases
VAS; Vasculotropin; VEGFA; VPF
Entrez Gene IDs
7422 (Human); 22339 (Mouse); 83785 (Rat); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Background
VEGF
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. The amino acid sequence of VEGF exhibits primary structural, as well as limited amino acid sequence, homology with that of the A and B chains of PDGF. All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Based on its homology with VEGF, PlGF was also proposed to be an angiogenic factor. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF with high affinity.In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has been shown to stimulate von Willebrand factor release from endothelial cells and induce expression of tissue factor activity in endothelial cells as well as in monocytes. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. It promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix. The modified extracellular matrix subsequently promotes the migration of macrophages, fibroblasts and endothelial cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. Elevated levels of VEGF have been reported in synovial fluids of rheumatoid arthritis patients and in sera from cancer patients.

目次に戻る

Citations

Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.

目次に戻る

お問い合わせ先

(テクニカルサポート 試薬担当)

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。